← All trials
NCT03514108
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2018
- Primary completion
- Mar 1, 2023
- Completion date
- Sep 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aarhus UniversityLead sponsor
- Aarhus UniversitySponsor investigator
- Danish Heart FoundationCollaborator
- Danish Council for Independent ResearchCollaborator
- Aarhus UniversityStudy chair
- Aarhus UniversityOverall official - principal investigator
- University of CopenhagenStudy chair
- University of CopenhagenOverall official - principal investigator
- The Aase og Ejnar Danielsen FoundationCollaborator
- Danish Heart FoundationStudy chair
- The Danish Regions: Foundation for Medical ResearchCollaborator
- Novo NordiskCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.